COMICE logo

COMICE

A randomised double blind placebo controlled Phase II clinical trial of Cediranib and Olaparib maintenance in advanced recurrent Cervical Cancer (COMICE)

COMICE

A randomised double blind placebo controlled Phase II clinical trial of Cediranib and Olaparib maintenance in advanced recurrent Cervical Cancer (COMICE)
Funding AstraZeneca
Portfolio Cancer
Interventions Medicine
Randomised Yes
Status Recruiting
Start Date 13-Sep-2018

This trial is looking at whether olaparib and cediranib can improve treatment for cancer of the cervix that has spread or come back.

Cancer Research UK supports this trial.
-------------------------------
The usual treatment for cancer of the cervix is a combination of chemotherapy and radiotherapy. You have more chemotherapy if the cancer spreads elsewhere in the body or comes back. This is advanced cervical cancer. But sometimes it comes back again. So, doctors are looking for ways to improve treatment.

In this trial, they are looking at olaparib and cediranib. They are both targeted drugs that work in different ways.

Olaparib is a PARP inhibitor. It blocks an enzyme called PARP which helps damaged cells to repair themselves.

Cediranib stops cancers from being able to make new blood vessels. They need these to grow.

Researchers think that having both drugs can shrink or stop the cancer growing. This may increase the time before the cancer starts to grow again after chemotherapy.

In this trial, some people have cediranib and olaparib. And some have dummy drugs (placebo).